CompletedNot Applicable

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

United States30 participantsStarted 2022-12-06

Plain-language summary

This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age of 21 and older * Uncontrolled cancer-associated pain (pain score of \>5 on NRS) despite oral use of 60 mg/d morphine equivalent a week prior to screening * Adverse side effects from long term opioid use defined as limiting or severely affecting patient's day to day function * Life expectancy of \> 3 months Exclusion Criteria: * Active infections * Controlled pain without adverse side effects that are limiting day to day function * Mechanical barriers * Obstruction of Cerebrospinal Fluid (CSF)

What they're measuring

Change in Pain Intensity from Screening through 3-Months

Timeframe: 3-Months

Change in Pain Interference from Screening through 3-Months

Timeframe: 3-Months

Trial details

NCT IDNCT05674240

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-20

View on ClinicalTrials.gov More Cancer Pain trials